Phase 3 Daraxonrasib Trial Nearly Doubles Survival In Metastatic Pancreatic Cancer
1h
2
On Sunday, May 31, 2026, researchers presented full randomized data at the American Society of Clinical Oncology meeting in Chicago showing daraxonrasib nearly doubled survival for previously treated metastatic pancreatic cancer patients. NPR